Search clinical trials for: Second line treatment for advanced lung cancer

Total 399502 results

Changhai Hospital
Shanghai Chest Hospital; Shanghai Changzheng Hospital; First Affiliated Hospital... and other collaborators

Recruiting

High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

Non-Small Cell Lung Cancer

China
University Hospital, Essen
German Cancer Aid

Not yet recruiting

Exercise in Patients With Advanced Non-small Cell Lung Cancer (BREATH)

Advanced Lung Carcinoma | NSCLC Stage IV | NSCLC Stage IIIB | First Line Treatment | Second Line Treatment | Palliative Treatment | NSCLC Stage IIIC

Germany
Peking University First Hospital
Merck Sharp & Dohme LLC

Not yet recruiting

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung Cancer

China
Akeso

Not yet recruiting

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Locally Advanced or Metastatic NSCLC

China
Fudan University

Not yet recruiting

Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC

Advanced Non-Small Cell Lung Cancer
Suzhou Puhe Pharmaceutical Technology Co., LTD

Not yet recruiting

YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

China
Advenchen Pharmaceuticals, LLC.

Recruiting

Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC

Small Cell Lung Cancer

United States
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

Metastatic Non Small Cell Lung Cancer

United States, China, Belgium, Portugal, Japan, Taiwan, France, United Kingdom, Spain, Hungary, Thailand, Germany, Italy, Switzerland, Hong Kong, Korea, Republic of, Australia, Mexico, Brazil, Netherlands, Romania, Argentina, Chile, G... and more
National Cancer Institute (NCI)

Recruiting

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage IV Hypopharyngeal... and other conditions

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer

Advanced Lung Carcinoma

China
Seagen Inc.
Merck Sharp & Dohme LLC; Genmab

Recruiting

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors (innovaTV 207)

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Exocrine Pancreatic Cancer | Carcinoma, Squamous Cell of Head and Neck

United States, Canada, France, Germany, Italy, Spain, United Kingdom, Puerto Rico
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States, Canada
TJ Biopharma Co., Ltd.

Withdrawn

Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

First-line Non-small-cell Lung Cancer | First-line Urothelial Carcinoma | Second-line Urothelial Carcinoma | Second-line Melanoma

China
Takeda

Active, not recruiting

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

United States, Spain, France, Korea, Republic of, Israel, Hong Kong, Australia, Taiwan, United Kingdom, Canada, Turkey, Italy, China, Germany, Russian Federation, Switzerland, Austria, Japan, Denmark, Belgium, Greece, Netherlands, P... and more
AstraZeneca

Completed

Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. (SELECT-2)

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

United States, Poland, France, Germany, Brazil, Hungary, Netherlands, Bulgaria
AstraZeneca

Active, not recruiting

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1)

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

United States, Canada, France, Italy, Spain, United Kingdom, Belgium, Poland, Brazil, Germany, Hungary, Peru, Russian Federation, Turkey, Australia, Chile, Austria, Netherlands, Portugal, Israel, Mexico, Romania, Sweden, Ukraine, Bulgaria, Argenti...
Celgene

Completed

Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer (abound2L+)

Carcinoma, Non-Small-Cell Lung

United States, Canada, France, Germany, Italy, Spain, United Kingdom
Fudan University

Enrolling by invitation

Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Envafolimab and Lenvatinib Combined With Paclitaxel-albumin

Gastric / Gastroesophageal Junction Adenocarcinoma

China
Yuhan Corporation

Completed

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Non-small Cell Lung Cancer
Shanghai Henlius Biotech

Active, not recruiting

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Squamous Non Small Cell Lung Cancer

China, Turkey, United States, Georgia, Poland, Russian Federation, Ukraine
National Cancer Institute, Naples

Active, not recruiting

Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer (BEVERLY)

Non-squamous Non-small Cell Lung Cancer

Italy
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and Cyprus (LUCENCE)

Non-Small Cell Lung Cancer

Greece
Hunan Cancer Hospital
Suzhou Sheng Diya Biomedical Co., Ltd.

Active, not recruiting

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Adenocarcinoma of the Lung

China
National Cancer Institute (NCI)

Completed

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | FGFR1 Gene Mutation | FGFR3 Gene Amplification

United States, Canada
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

CCND1 Gene Amplification | CCND2 Gene Amplification | CCND3 Gene Amplification | CDK4 Gene Amplification | Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States
Novartis Pharmaceuticals

Terminated

A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer (ATTRACT-2)

Non-Small Cell Lung Cancer

United States, Germany, Belgium, Italy, France, Canada, Hungary, Poland, Switzerland, Spain
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer

Head and Neck Cancer | Skin Reactions Secondary to Radiation Therapy

United States, Canada
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer

Advanced Non-squamous Cell Non-small Cell Lung Cancer

China
Second Affiliated Hospital of Nanchang University
Nanchang University

Unknown

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

Non-small Cell Lung Cancer | EGFR Gene Mutation

China
Sichuan Cancer Hospital and Research Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC

Lung Cancer | Lung Cancer Metastatic

China
Guangzhou Institute of Respiratory Disease
GeneCast Biotechnology Co., Ltd.

Unknown

Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform

Lung Cancer Non-small Cell Stage IV

China
China Medical University, China
General Hospital of Shenyang Military Region; Shengjing Hospital; Liaoning Tumor... and other collaborators

Unknown

Endostar First-line Treatment of Advanced NSCLC

Non Small Cell Lung Cancer
Hoffmann-La Roche

Completed

A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

Russian Federation
Yonsei University

Withdrawn

An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

NSCLC (Non-Small Cell Lung Cancer)
National Cancer Institute, Naples
University of Alberta; University of Campania "Luigi Vanvitelli"; Princess Margaret... and other collaborators

Completed

TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer (TORCH)

Advanced Non-Small Cell Lung Cancer

Italy, Canada
National Cancer Institute, Naples

Terminated

The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer (DISTAL-2)

Advanced Non-Small Cell Lung Cancer

Italy
Hoffmann-La Roche

Completed

An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy (TIME)

Non-Squamous Non-Small Cell Lung Cancer

Belgium
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; Southwest Oncology... and other collaborators

Terminated

Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer (MARVEL)

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States, Canada
Pfizer

Completed

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Non-small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Australia, Brazil, Spain, United Kingdom, Singapore, Canada, Hong Kong, Poland, Puerto Rico
Pharmacyclics LLC.

Terminated

Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)

Lung Cancer

United States, Canada, Russian Federation, Serbia
INSYS Therapeutics Inc
National Cancer Institute (NCI)

Completed

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Cancer

United States
Kunming Medical University

Terminated

CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

China
Pharmacyclics LLC.

Terminated

Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

Non-Small Cell Lung Carcinoma

United States
Veeda Oncology
Bristol-Myers Squibb

Completed

A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Sun Yat-sen University

Completed

A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung

Non-small Cell Lung Cancer

China
University Hospital, Limoges
Groupe Français de Pneumo-Cancérologie

Completed

Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

France
Gruppo Oncologico Italiano di Ricerca Clinica

Unknown

Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC

Advanced Non-Small Cell Lung Cancer

Italy
National Cheng-Kung University Hospital

Unknown

Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

Non-Small Cell Lung Cancer

Taiwan
Kentuckiana Cancer Institute

Completed

Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States

Search clinical trials for: Second line treatment for advanced lung cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations